Bacil Pharma Valuation

Q: What is the Fair Price of 524516 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

524516 (₹44.44) is trading above our estimate of [[fair value]] (₹1.4)

Is 524516 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 524516 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 524516 (₹44.44) is trading above our estimate of fair value (₹1.4)

Significantly Below Fair Value: 524516 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524516?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 524516. This is calculated by dividing 524516's market cap by their current preferred multiple.
What is 524516's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	₹261.75m

524516 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-112x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 524516's PE Ratio compare to its peers?

The above table shows the PE ratio for 524516 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	53.9x
SUNREST Sunrest Lifescience	104.7x	n/a	₹236.2m
524400 Ishita Drugs and Industries	29.9x	n/a	₹227.1m
524768 Emmessar Biotech & Nutrition	27.2x	n/a	₹213.0m
VILINBIO Vilin Bio Med	n/a	n/a	₹299.9m
524516 Bacil Pharma	68x	n/a	₹261.8m

Price-To-Earnings vs Peers: 524516 is expensive based on its Price-To-Earnings Ratio (68x) compared to the peer average (24.9x).

Price to Earnings Ratio vs Industry

How does 524516's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.2%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.2%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 524516 is expensive based on its Price-To-Earnings Ratio (68x) compared to the Indian Pharmaceuticals industry average (37.7x).

Price to Earnings Ratio vs Fair Ratio

What is 524516's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524516 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	68x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 524516's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.